drugset / Trial / NCT01605435

Ghrelin Dose Finding In Frail Elderly

NCT01605435

Phase 2 Completed 5 enrolled University of Pennsylvania
Non-randomizedParallel-groupSingle-blindOther

Summary

Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting (sarcopenia) and unintentional weight loss. There are currently no approved therapies for frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the brain. The purpose of this study is to determine the optimal subcutaneous ghrelin dose as a potential intervention for frail elderly individuals. We will examine food intake and metabolic parameters after placebo and ghrelin administration at three escalating subcutaneously administered doses.

Timeline

Start
2012-05
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ghrelin Peptide 2 ug/kg Subcutaneous
Subject Ghrelin Peptide 5 ug/kg Subcutaneous
Subject Ghrelin Peptide 7.5 ug/kg Subcutaneous
Subject Ghrelin Peptide 10 ug/kg Subcutaneous

Indications

No indication recorded.